VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Virax Biolabs Group Ltd
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026
$1.40−0.05 (-3.45%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Virax Biolabs Group Ltd revenue by segment
By business segment
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Test Kit Sales | $12.42K | $6.33K | $156.42K | $8.56K | – | 100.0% | +96.2% |
| Consulting Revenues | – | – | – | – | $19.00K | – | – |
| ViraxClear and ViraxCare Revenue | – | – | – | – | $104.82K | – | – |
| Virax Clear | – | – | $156.42K | $8.56K | – | – | – |
By region
From the segment and revenue-disaggregation notes of Virax Biolabs's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.